Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
City of Hope National Medical Center, Duarte, California Sarah Cannon Research Institute at HealthOne, Denver, Colorado Florida Cancer Specialists and Research Institute, St. Petersburg, Florida Massachusetts General Hospital, Boston, Massachusetts START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan Washington University School of Medicine in St. Louis, St Louis, Missouri Icahn School of Medicine at Mount Sinai, New York, New York Columbia University Irving Medical Center, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Sarah Cannon Research Institute, Nashville, Tennessee University of Texas MD Anderson Cancer Center, Houston, Texas South Texas Accelerated Research Therapeutics (START), San Antonio, Texas START Mountain Region, West Valley City, Utah Australia
St Vincent's Hospital, Darlinghurst Linear Clinical Research, Nedlands China
Beijing Cancer hospital, Beijing Sun Yat-sen University Cancer Center, Guangzhou Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai France
Institut Gustave Roussy (Igr), Villejuif Japan
National Cancer Center Hospital East, Kashiwa, Chiba Aichi Cancer Center Hospital, Nagoya South Korea
Asan Medical Center, Seoul Spain
Catalan Institute of Oncology Duran i Reynals Hospital, Barcelona Hospital Universitario 12 de Octubre, Madrid Hospital Madrid Norte Sanchinarro, Madrid Hospital Universitario Virgen Del Rocio, Seville United Kingdom
St Bartholomew's Hospital, London The Christie NHS Foundation Trust, Manchester